Cortical Cholinergic Lesion Causes Aβ Deposition: Cholinergic-Amyloid Fusion Hypothesis

[1]  T. Beach,et al.  Immunotoxin Lesion of the Cholinergic Nucleus Basalis Causes Aβ Deposition: Towards a Physiologic Animal Model of Alzheimers Disease , 2003 .

[2]  S. Younkin,et al.  Plasma Levels of Aβ42 and Aβ40 in Alzheimer Patients during Treatment with the Acetylcholinesterase Inhibitor Tacrine , 2002, Dementia and Geriatric Cognitive Disorders.

[3]  P. Kelly,et al.  Cholinergic Changes in the APP23 Transgenic Mouse Model of Cerebral Amyloidosis , 2002, The Journal of Neuroscience.

[4]  S. Wisniewski,et al.  Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment , 2002, Annals of neurology.

[5]  B. Sommer.  Alzheimer's disease and the amyloid cascade hypothesis: ten years on. , 2002, Current opinion in pharmacology.

[6]  Raymond Scott Turner,et al.  Animal Model Stable -Secretase Activity and Presynaptic Cholinergic Markers During Progressive Central Nervous System Amyloidogenesis in Tg2576 Mice , 2002 .

[7]  T. Beach,et al.  Reduction of cortical amyloid β levels in guinea pig brain after systemic administration of physostigmine , 2001, Neuroscience Letters.

[8]  E. Mufson,et al.  Neuropathology of Mice Carrying Mutant APPswe and/or PS1M146L Transgenes: Alterations in the p75NTR Cholinergic Basal Forebrain Septohippocampal Pathway , 2001, Experimental Neurology.

[9]  T. Beach,et al.  Reduction of cerebrospinal fluid amyloid β after systemic administration of M1 muscarinic agonists , 2001, Brain Research.

[10]  I. McDowell,et al.  Alzheimer’s disease: Insights from epidemiology , 2001, Aging.

[11]  E. McGowan,et al.  Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes , 2001, Neuroreport.

[12]  J. Growdon,et al.  The selective muscarinic M1 agonist AF102B decreases levels of total Aβ in cerebrospinal fluid of patients with Alzheimer's disease , 2000, Annals of neurology.

[13]  J. Growdon,et al.  Treatment with the Selective Muscarinic Agonist Talsaclidine Decreases Cerebrospinal Fluid Levels of Total Amyloid β‐Peptide in Patients with Alzheimer's Disease , 2000, Annals of the New York Academy of Sciences.

[14]  L. Thal,et al.  The decline in synapses and cholinergic activity is asynchronous in Alzheimer’s disease , 2000, Neurology.

[15]  A. Fisher.  Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists. , 2000, Japanese journal of pharmacology.

[16]  S. Gandy,et al.  Ovariectomy and 17β-estradiol modulate the levels of Alzheimer’s amyloid β peptides in brain , 2000, Neurology.

[17]  D. Moechars,et al.  Acetylcholinesterase-Positive Fiber Deafferentation and Cell Shrinkage in the Septohippocampal Pathway of Aged Amyloid Precursor Protein London Mutant Transgenic Mice , 2000, Neurobiology of Disease.

[18]  B. Vincent,et al.  Effect of estradiol on neuronal Swedish-mutated beta-amyloid precursor protein metabolism: reversal by astrocytic cells. , 2000, Biochemical and biophysical research communications.

[19]  T. Beach,et al.  The Cholinergic Deficit Coincides with Aβ Deposition at the Earliest Histopathologic Stages of Alzheimer Disease , 2000, Journal of neuropathology and experimental neurology.

[20]  W. Honer,et al.  Cortical Cholinergic Denervation Elicits Vascular Aβ Deposition , 2000 .

[21]  R. Weller,et al.  Cerebral Amyloid Angiopathy: Accumulation of Aβ in Interstitial Fluid Drainage Pathways in Alzheimer's Disease , 2000, Annals of the New York Academy of Sciences.

[22]  T. Beach,et al.  Cholinergic deafferentation of the rabbit cortex: a new animal model of Aβ deposition , 2000, Neuroscience Letters.

[23]  C. Cotman,et al.  Region-specific age at onset of β-amyloid in dogs☆ , 2000, Neurobiology of Aging.

[24]  O. Isacson,et al.  Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  F. Gage,et al.  Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  D A Bennett,et al.  Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease , 1999, The Journal of comparative neurology.

[27]  K. Davis,et al.  Cholinergic markers in elderly patients with early signs of Alzheimer disease. , 1999, JAMA.

[28]  K. Duff,et al.  Reorganization of Cholinergic Terminals in the Cerebral Cortex and Hippocampus in Transgenic Mice Carrying Mutated Presenilin-1 and Amyloid Precursor Protein Transgenes , 1999, The Journal of Neuroscience.

[29]  G. Leanza.  Chronic elevation of amyloid precursor protein expression in the neocortex and hippocampus of rats with selective cholinergic lesions , 1998, Neuroscience Letters.

[30]  Yu-Min Kuo,et al.  Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. , 1998, The American journal of pathology.

[31]  F. Bymaster,et al.  Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects , 1998, Brain Research.

[32]  S. Younkin.  The role of Aβ42 in Alzheimer's disease , 1998, Journal of Physiology-Paris.

[33]  K Namekata,et al.  Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease. , 1998, The American journal of pathology.

[34]  B. Greenberg,et al.  Turnover of Amyloid β-Protein in Mouse Brain and Acute Reduction of Its Level by Phorbol Ester , 1998, The Journal of Neuroscience.

[35]  T. Deacon,et al.  Chronic cognitive deficits and amyloid precursor protein elevation after selective immunotoxin lesions of the basal forebrain cholinergic system , 1998, Neuroreport.

[36]  N. Robakis,et al.  Alzheimer's disease: a re-examination of the amyloid hypothesis , 1998, Trends in Neurosciences.

[37]  U. Ueberham,et al.  In Vivo Regulation of Amyloid Precursor Protein Secretion in Rat Neocortex by Cholinergic Activity , 1997, European Journal of Neuroscience.

[38]  C. J. Maclean,et al.  Learning impairments following injection of a selective cholinergic immunotoxin, ME20.4 IgG-saporin, into the basal nucleus of Meynert in monkeys , 1997, Neuroscience.

[39]  R. Nitsch,et al.  Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain. , 1997, Life sciences.

[40]  L. H. Hughes,et al.  Cholinergic fibre loss associated with diffuse plaques in the non-demented elderly: the preclinical stage of Alzheimer’s disease? , 1997, Acta Neuropathologica.

[41]  A. Fisher,et al.  Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum , 1996, Brain Research.

[42]  A. Palmer.  Neurochemical studies of Alzheimer's disease. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[43]  A. Procter.  Neurochemical correlates of dementia. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[44]  R. Nitsch.  From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer's disease. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[45]  R. Wiley,et al.  Central noradrenergic lesioning using anti-DBH-saporin: anatomical findings , 1996, Brain Research.

[46]  B. Greenberg,et al.  Enhanced Amyloidogenic Processing of the β-Amyloid Precursor Protein in Gene-targeted Mice Bearing the Swedish Familial Alzheimer's Disease Mutations and a “Humanized” Aβ Sequence* , 1996, The Journal of Biological Chemistry.

[47]  Brian J Cummings,et al.  Diffuse plaques contain C-terminal Aβ 42 and not Aβ 40: Evidence from cats and dogs , 1996, Neurobiology of Aging.

[48]  L. H. Hughes,et al.  Increased β-amyloid precursor protein mRNA in the rat cerebral cortex and hippocampus after chronic systemic atropine treatment , 1996, Neuroscience Letters.

[49]  J. Growdon,et al.  Regulation of APP Processing Potential for the Therapeutical Reduction of Brain Amyloid Burden a , 1996, Annals of the New York Academy of Sciences.

[50]  T. J. Walsh,et al.  Behavioral and neurobiological alterations induced by the immunotoxin 192-IgG-saporin: cholinergic and non-cholinergic effects following i.c.v. injection , 1995, Brain Research.

[51]  S. Farber,et al.  Regulated secretion of beta-amyloid precursor protein in rat brain , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[52]  B. de Strooper,et al.  Production of intracellular amyloid‐containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence. , 1995, The EMBO journal.

[53]  F. Bymaster,et al.  The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster ovary-m1 cells. , 1995, Life sciences.

[54]  D. Gurwitz,et al.  NGF promotes amyloid precursor protein secretion via muscarinic receptor activation. , 1995, Biochemical and biophysical research communications.

[55]  K. Davis,et al.  Chronic elevation of secreted amyloid precursor protein in subcortically lesioned rats, and its exacerbation in aged rats , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[56]  C. Masters,et al.  Intracellular production of beta A4 amyloid of Alzheimer's disease: modulation by phosphoramidon and lack of coupling to the secretion of the amyloid precursor protein. , 1995, Biochemistry.

[57]  B. Wolf,et al.  Muscarinic Regulation of Alzheimer's Disease Amyloid Precursor Protein Secretion and Amyloid β-Protein Production in Human Neuronal NT2N Cells (*) , 1995, The Journal of Biological Chemistry.

[58]  S. L. Mobley,et al.  Behavioral, biochemical, histological, and electrophysiological effects of 192 IgG-saporin injections into the basal forebrain of rats , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[59]  B T Hyman,et al.  Neuropathology and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[60]  D. Gurwitz,et al.  Amyloid precursor protein secretion via muscarinic receptors: reduced desensitization using the M1-selective agonist AF102B. , 1994, Biochemical and biophysical research communications.

[61]  J. Growdon,et al.  Role of neurotransmission in the regulation of amyloid beta-protein precursor processing. , 1994, Biochemical pharmacology.

[62]  D. Wong,et al.  Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232). , 1994, The Journal of pharmacology and experimental therapeutics.

[63]  F. Gage,et al.  Age and damage induced changes in amyloid protein precursor immunohistochemistry in the rat brain , 1994, The Journal of comparative neurology.

[64]  J. Morrison,et al.  Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. , 1994, Cerebral cortex.

[65]  C. Geula,et al.  Complete and selective cholinergic denervation of rat neocortex and hippocampus but not amygdala by an immunotoxin against the p75 NGF receptor , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[66]  R. Wiley,et al.  192 IgG-saporin : I. Specific Lethality for Cholinergic Neurons in the Basal Forebrain of the Rat , 1994, Journal of neuropathology and experimental neurology.

[67]  J. Muir,et al.  Excitotoxic lesions of basal forebrain cholinergic neurons: Effects on learning, memory and attention , 1993, Behavioural Brain Research.

[68]  J. Growdon,et al.  Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. , 1993, The Journal of biological chemistry.

[69]  K. Davis,et al.  Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[70]  P. Francis,et al.  Neurotransmitters and Second Messengers in Aging and Alzheimer's Disease , 1993, Annals of the New York Academy of Sciences.

[71]  Charles Duyckaerts,et al.  Beta A4 deposits are constant in the brain of the oldest old: an immunocytochemical study of 20 French centenarians. , 1993, Neurobiology of aging.

[72]  P. Greengard,et al.  Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[73]  P. Kotikalapudi,et al.  Sequence and nethylation in the βA4 region of the rabbit anyloid precursor protein gene , 1992 .

[74]  J. Growdon,et al.  Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. , 1992, Science.

[75]  R. Wiley,et al.  Specificity of 192 IgG-saporin for NGF receptor-positive cholinergic basal forebrain neurons in the rat , 1992, Brain Research.

[76]  T. Beach,et al.  Cholinergic fiber loss occurs in the absence of synaptophysin depletion in Alzheimer's disease primary visual cortex , 1992, Neuroscience Letters.

[77]  P. Davies,et al.  Persistent innervation of the rat neocortex by basal forebrain cholinergic neurons despite the massive reduction of cortical target neurons II. Neurochemical analysis , 1992, Experimental Neurology.

[78]  E. Perry,et al.  Convergent cholinergic activities in aging and Alzheimer's disease , 1992, Neurobiology of Aging.

[79]  N. Lindefors,et al.  Widespread neuronal degeneration after ibotenic acid lesioning of cholinergic neurons in the nucleus basalis revealed by in situ hybridization , 1992, Neuroscience Letters.

[80]  R. Wiley,et al.  Immunolesioning: selective destruction of neurons using immunotoxin to rat NGF receptor , 1991, Brain Research.

[81]  D. Price,et al.  Neurotransmitters in neocortex of aged rhesus monkeys , 1991, Neurobiology of Aging.

[82]  D. Price,et al.  Aged Non‐Human Primates: An Animal Model of Age‐Associated Neurodegenerative Disease , 1991, Brain pathology.

[83]  S. Little,et al.  Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis. , 1991, Brain research. Molecular brain research.

[84]  K. Davis,et al.  Increased biosynthesis of Alzheimer amyloid precursor protein in the cerebral cortex of rats with lesions of the nucleus basalis of Meynert. , 1991, Brain research. Molecular brain research.

[85]  H. Braak,et al.  Demonstration of Amyloid Deposits and Neurofibrillary Changes in Whole Brain Sections , 1991, Brain pathology.

[86]  S. Gershon,et al.  Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[87]  G. Buzsáki,et al.  Nucleus basalis lesions fail to induce senile plaques in the rat , 1990, Experimental Neurology.

[88]  C. Geula,et al.  Cortical cholinergic fibers in aging and Alzheimer's disease: A morphometric study , 1989, Neuroscience.

[89]  D. Price,et al.  Age-related changes in multiple neurotransmitter systems in the monkey brain , 1989, Neurobiology of Aging.

[90]  R. Martins,et al.  A4 amyloid protein deposition and the diagnosis of Alzheimer's disease , 1988, Neurology.

[91]  P. Francis,et al.  Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer's disease. , 1988, Brain : a journal of neurology.

[92]  M. Esiri,et al.  Topographical distribution of neurochemical changes in Alzheimer's disease , 1988, Journal of the Neurological Sciences.

[93]  R. Katzman.,et al.  Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques , 1988, Annals of neurology.

[94]  W. Millard,et al.  Long-term neuropathological and neurochemical effects of nucleus basalis lesions in the rat. , 1987, Science.

[95]  H. Kimura,et al.  Perfusion-fixation of the human brain for immunohistochemistry: comparison with immersion-fixation , 1987, Journal of Neuroscience Methods.

[96]  D. Price,et al.  Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer's disease. , 1987, Science.

[97]  T. Maeda,et al.  Visualization of detailed acetylcholinesterase fiber and neuron staining in rat brain by a sensitive histochemical procedure. , 1986, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[98]  D. Francis,et al.  INACTIVATION OF HTLV-III/LAV-INFECTED CULTURES OF NORMAL HUMAN LYMPHOCYTES BY NONOXYNOL-9 IN VITRO , 1985, The Lancet.

[99]  D. Neary,et al.  Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment. , 1985, The New England journal of medicine.

[100]  E. Perry,et al.  A review of neuropathological and neurochemical correlates of Alzheimer's disease. , 1985, Danish medical bulletin.

[101]  T. Arendt,et al.  Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in alzheimer's disease , 1985, Neuroscience.

[102]  P. Yates,et al.  Monoaminergic neurotransmitter systems in presenile Alzheimer's disease and in senile dementia of Alzheimer type. , 1984, Clinical neuropathology.

[103]  P. Mcgeer,et al.  Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain , 1984, Neurology.

[104]  L. Iversen,et al.  Correlation of cortical cholinergic and GABA deficits with quantitative neuropathological findings in senile dementia. , 1984, Brain : a journal of neurology.

[105]  P. Yates,et al.  ALZHEIMER'S PRESENILE DEMENTIA, SENILE DEMENTIA OF ALZHEIMER TYPE AND DOWN'S SYNDROME IN MIDDLE AGE FORM AN AGE RELATED CONTINUUM OF PATHOLOGICAL CHANGES , 1984, Neuropathology and applied neurobiology.

[106]  D. Mann,et al.  Changes in nerve cells of the nucleus basalis of Meynert in Alzheimer's disease and their relationship to ageing and to the accumulation of lipofuscin pigment , 1984, Mechanisms of Ageing and Development.

[107]  S. M. Sumi,et al.  Alzheimer's disease: Choline acetyltransferase activity in brain tissue from clinical and pathological subgroups , 1983, Annals of neurology.

[108]  D. Neary,et al.  Biochemical Assessment of Serotonergic and Cholinergic Dysfunction and Cerebral Atrophy in Alzheimer's Disease , 1983, Journal of neurochemistry.

[109]  J. S. Benton,et al.  Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients , 1982, Journal of the Neurological Sciences.

[110]  D. Price,et al.  Cholinergic innervation in neuritic plaques. , 1982, Science.

[111]  L. Iversen,et al.  CHOLINERGIC DEFICIT IN FRONTAL CEREBRAL CORTEX IN ALZHEIMER'S DISEASE IS AGE DEPENDENT , 1981, The Lancet.

[112]  E. Perry,et al.  Neurochemical activities in human temporal lobe related to aging and Alzheimer-type changes , 1981, Neurobiology of Aging.

[113]  A. Fisher,et al.  The AF64a-treated mouse: possible model for central cholinergic hypofunction. , 1981, Science.

[114]  J. Coyle,et al.  Evidence for a cholinergic projection to neocortex from neurons in basal forebrain. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[115]  F. Fonnum,et al.  Radiochemical micro assays for the determination of choline acetyltransferase and acetylcholinesterase activities. , 1969, The Biochemical journal.

[116]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[117]  T. Beach,et al.  Senile plaques, amyloid β-protein, and acetylcholinesterase fibres: laminar distributions in Alzheimer's disease striate cortex , 2004, Acta Neuropathologica.

[118]  H. Braak,et al.  Evolution of Alzheimer’s disease-related cytoskeletal changes in the basal nucleus of Meynert , 2000, Acta Neuropathologica.

[119]  R. Nitsch,et al.  Lu 25-109, a combined m1 agonist and m2 antagonist, modulates regulated processing of the amyloid precursor protein of Alzheimer's disease , 1998, Journal of Neural Transmission.

[120]  R. Wiley,et al.  192 IgG-saporin. 2. Neuropathology in the rat brain. , 1995 .

[121]  H. Mantsch,et al.  Human and rodent Alzheimer beta-amyloid peptides acquire distinct conformations in membrane-mimicking solvents. , 1993, European journal of biochemistry.

[122]  D. Czepita.  Influence of alpha and beta-adrenergic stimulators and blockers on the electroretinogram and visually evoked potentials of the rabbit. , 1990, Biomedica biochimica acta.

[123]  H. Gertz,et al.  The basal nucleus of Meynert revised: the nerve cell number decreases with age. , 1989, Archives of gerontology and geriatrics.

[124]  T. Powell,et al.  Anterograde vs. retrograde degeneration of the nucleus basalis medialis in Alzheimer's disease. , 1987, Journal of neural transmission. Supplementum.

[125]  G. Roch,et al.  Light and electron microscopical observations in the nucleus basalis of Meynert and in hippocampus of the rat after injection of a cholinotoxin: degeneration and reorganization. , 1987, Zeitschrift fur mikroskopisch-anatomische Forschung.